The Innovative Medicines Initiative (IMI) is a Joint Technology Initiative (JTI) between the European Union, represented by the European Commission (EC), and the European Federation of Pharmaceutical Industries and Associations (EFPIA). IMI is currently the world's largest public-private partnership, or PPP, in the biomedical sciences (Box 1). The IMI was set up to boost the competitiveness of Europe in the biopharmaceutical field. IMI was launched in 2008, upon identification of the key bottlenecks in research that should be overcome to stimulate innovation in the drug development process.1 IMI brings the different stakeholders (pharmaceutical companies, small- and medium-sized enterprises [SMEs], universities, public research laboratories, patient organizations [POs], and healthcare regulators) together in PPPs. The IMI is situated at a pre-discovery or proof-of-concept (POC) stage and covers early research to improve needed and poorly understood science. The IMI Strategic Research Agenda (SRA), targeting key challenges such as safety and efficacy prediction, knowledge management, and education and training, was implemented to enhance the competitiveness of the pharmaceutical sector in Europe for the benefit of patients and scientists.2 In 2009, the first IMI consortia conducting projects addressing the SRA key challenges were initiated. Since then, IMI has already launched 49 consortia via 11 competitive Calls, and project execution of IMI projects will run until end of 2017.3 The total budget allocated to IMI is two billion euros (2008–2014), money equally invested by the EC (cash contribution) and EFPIA (in-kind and cash contribution).4 Box 1. Innovative Medicines Initiative (IMI) in Numbers

中文翻译：

---

创新药物计划 (IMI) 案例研究分析揭示了早期公私合作伙伴关系 (PPP) 的真正附加值

创新药物计划 (IMI) 是由欧盟委员会 (EC) 代表的欧盟与欧洲制药工业和协会联合会 (EFPIA) 之间的联合技术计划 (JTI)。IMI 是目前世界上最大的生物医学科学公私合作伙伴关系或 PPP（方框 1）。IMI 的成立是为了提高欧洲在生物制药领域的竞争力。IMI 于 2008 年启动，确定了应克服的研究中的关键瓶颈，以刺激药物开发过程中的创新。 1 IMI 带来了不同的利益相关者（制药公司、中小企业 [SME]、大学、公共研究实验室、患者组织 [PO] 和医疗保健监管机构）一起在 PPP 中。IMI 处于发现前或概念验证 (POC) 阶段，涵盖早期研究，以改进所需的和知之甚少的科学。实施 IMI 战略研究议程 (SRA)，针对安全性和有效性预测、知识管理以及教育和培训等关键挑战，旨在提高欧洲制药业的竞争力，造福患者和科学家。 2 2009 年，第一个 IMI 财团发起了解决 SRA 关键挑战的项目。从那时起，IMI 已经通过 11 个竞争性电话发起了 49 个财团，IMI 项目的项目执行将持续到 2017 年底。3 分配给 IMI 的总预算为 20 亿欧元（2008-2014 年），由 EC 平均投资的资金（现金捐款）和 EFPIA（实物和现金捐款）。4 框 1。